Related by context. All words. (Click for frequent words.) 65 perifosine 64 tesmilifene 64 Nimotuzumab 63 clofarabine 62 obatoclax 62 CYT# 62 satraplatin 62 dirucotide 62 TheraCIM 62 Proxinium TM 61 apaziquone 61 tivozanib 61 Marqibo 61 FOLOTYN 61 OPAXIO 61 ADVEXIN 60 eniluracil 60 Virulizin R 60 AP# [003] 60 Oncoscience AG 60 PXD# 60 DCVax R Brain 59 MGCD# [001] 59 Alpharadin 59 Neuradiab 59 TRISENOX 59 Multikine 59 tamibarotene 59 Dacogen injection 59 Amrubicin 59 alvespimycin 59 Insegia 59 randomized Phase 59 Azedra 59 belinostat 59 valopicitabine 58 Vicinium TM 58 registrational trial 58 HGS# 58 picoplatin 58 forodesine 58 TELCYTA 58 ZEVALIN 58 ozarelix 58 TELINTRA 58 blinatumomab 58 YM BioSciences 58 tanespimycin 58 phase IIb clinical 58 INCB# [001] 58 Tamibarotene 58 Advexin 58 Allovectin 7 ® 58 oral ridaforolimus 58 Phase IIIb clinical 58 Loramyc ® 58 voclosporin 58 carfilzomib 58 brentuximab vedotin 57 lapatinib 57 registrational 57 ABRAXANE 57 Perifosine 57 UPLYSO 57 ofatumumab 57 talactoferrin 57 SUTENT 57 bavituximab 57 elesclomol 57 clinical trials 57 PROVENGE 57 IMGN# 57 Oncophage 57 OncoVEX GM CSF 57 axitinib 57 pralatrexate 57 Imprime PGG 57 T DM1 57 TNFerade 57 MBP# [001] 57 brain metastases 57 dose escalation 57 Amplimexon 57 Ceplene 57 HER2 positive metastatic breast 57 ZYBRESTAT 57 MOZOBIL 57 Loramyc R 57 OvaRex ® MAb 57 Tavocept 57 pertuzumab 57 Phase III clinical 57 AQ4N 56 ProLindac 56 ASA# 56 afatinib 56 tesetaxel 56 Stimuvax 56 Cotara 56 Soliris TM eculizumab 56 recurrent NSCLC 56 Fodosine 56 phase IIa clinical 56 Evoltra TM 56 Phase Ib 56 COMFORT II 56 EFAPROXYN 56 luliconazole 56 carboplatin paclitaxel 56 Telatinib 56 ixabepilone 56 INCB# [002] 56 PREOS 56 BiovaxID 56 amrubicin 56 Nexavar ® 56 ELACYT 56 fidaxomicin 56 trastuzumab DM1 56 REOLYSIN ® 56 zalutumumab 56 teduglutide 56 oral deforolimus 56 capecitabine 56 HspE7 56 autoimmune indications 56 TYSABRI 56 SIR Spheres 56 EOquin 56 AzaSite Plus 56 IMA# 56 Allovectin 7 R 56 Cloretazine R VNP#M 56 Lux Biosciences 56 pivotal Phase III 56 EOquin TM 56 BAY #-# 56 StemEx R 56 Combidex 56 bardoxolone 56 docetaxel 56 OncoVEX 56 Dacogen 55 MEK inhibitors 55 NEBIDO 55 Satraplatin 55 Ceflatonin 55 JAK inhibitor 55 PF # [001] 55 TREANDA 55 TYKERB 55 Allovectin 7 55 clinical trial 55 Prochymal 55 ONCASPAR 55 IRESSA 55 NEUMUNE 55 MyVax R 55 Phase III clinical trials 55 Traficet EN 55 Amigal 55 elacytarabine 55 ridaforolimus 55 Phase Ib study 55 TEMODAL 55 Vidaza 55 trastuzumab DM1 T DM1 55 UVIDEM 55 AEG# 55 oncology indications 55 isavuconazole 55 vandetanib 55 vinorelbine 55 ganetespib 55 ONCONASE 55 cintredekin besudotox 55 BLA filing 55 Irinotecan 55 Archexin 55 ZADAXIN 55 veltuzumab 55 Phase IIb clinical 55 hematologic malignancies 55 Urocidin 55 Cethrin 55 Zolinza 55 Taxotere ® 55 RG# [001] 55 PEG SN# 55 Vectibix 55 Plenaxis R 55 Rexin G 55 custirsen 55 temozolomide 55 omacetaxine 55 VELCADE 55 BrachySil 55 Alocrest 55 torezolid phosphate 55 Genasense 55 SNT MC# 55 BrachySil TM 55 rhC1INH 55 sapacitabine 55 Plenaxis TM 55 orBec R 55 phase IIb 55 ThermoDox ® 55 HuMax CD4 55 nonclinical studies 55 metastatic RCC 55 anticancer agent 54 Genasense ® 54 Tarvacin TM 54 HGS ETR1 54 zanolimumab 54 Vasovist 54 elotuzumab 54 Phase Ib II 54 ANA# 54 IRX 2 54 refractory multiple myeloma 54 XL# [003] 54 albinterferon alfa 2b 54 EndoTAG TM -1 54 Bronchitol 54 ENMD # 54 PROMACTA 54 Loramyc 54 pixantrone 54 PSMA ADC 54 Cloretazine ® 54 ERBITUX 54 Phase III trials 54 Bicifadine 54 Tarceva TM 54 vilazodone 54 REOLYSIN 54 Raptiva ® 54 OXi# 54 aflibercept 54 Phase 2b trial 54 pivotal Phase 54 PROSTVAC ® 54 mertansine 54 TOCOSOL Paclitaxel 54 HuMax EGFr 54 YONDELIS 54 Sym# 54 Soliris 54 AVN# [001] 54 IMC A# 54 Clolar 54 romidepsin 54 ThermoDox 54 CINTREDEKIN BESUDOTOX 54 castration resistant prostate cancer 54 sorafenib 54 Phase IIa trial 54 Phase IIb 54 palifosfamide 54 vidofludimus 54 subcutaneous formulation 54 PEG INTRON 54 bone metastases 54 bafetinib 54 NSCLC 54 #D#C# 54 ALN RSV# 54 glufosfamide 54 XYOTAX 54 methylnaltrexone 54 LEP ETU 54 Voraxaze ™ 54 Neulasta ® 54 TRISENOX ® 54 prGCD 54 CoFactor 54 Cellegesic 54 NP2 Enkephalin 54 TYZEKA 54 candidates bavituximab 54 VIDAZA 54 talabostat 54 lumiliximab 54 vorinostat 54 voreloxin 54 Azixa 54 Increlex ® 54 Canvaxin 54 Junovan 54 goserelin 54 phenoxodiol 54 preclinical studies 54 Abraxane 54 soft tissue sarcoma 53 Aphthasol R 53 HQK 53 Apaziquone 53 mapatumumab 53 Hepatocellular Carcinoma HCC 53 Phase 1b trial 53 Phase 2b study 53 sunitinib 53 BEXXAR 53 Phase IIIb study 53 MAGE A3 ASCI 53 metastatic colorectal cancer 53 Phase Ib clinical 53 relapsing multiple sclerosis 53 AZILECT ® 53 Urocidin TM 53 Phase 1b 53 invasive bladder 53 trabectedin 53 Phase #b/#a 53 IIa trial 53 Afatinib 53 PLX PAD 53 Cladribine Tablets 53 hematological cancers 53 CBLC# 53 Phase 2b clinical 53 DCVax ® Brain 53 Pixantrone 53 phase IIb trial 53 XmAb# 53 RhuDex ® 53 vosaroxin 53 hereditary deficiency 53 FTY# 53 Cloretazine 53 Cx# [002] 53 Multiferon R 53 OvaRex R 53 Scancell 53 Folotyn 53 huC# DM4 53 Locteron 53 clevudine 53 AZX# 53 Neulasta R 53 registrational studies 53 vemurafenib 53 HERmark 53 Sulonex TM 53 Targretin 53 cilengitide 53 BLA submission 53 Phase III pivotal 53 REOLYSIN R 53 refractory metastatic colorectal cancer 53 Symadex 53 Taxotere R 53 ThermoDox R 53 ruxolitinib 53 hormone refractory prostate cancer 53 ATryn R 53 BioNumerik 53 CEQ# 53 bendamustine 53 Fludara 53 dalbavancin 53 panitumumab 53 investigational 53 metastatic renal cell carcinoma 53 hematological malignancies 53 BiTE antibody 53 refractory CLL 53 QUADRAMET 53 Shigamabs ® 53 TORISEL 53 dose cohorts 53 Icatibant 53 Cotara R 53 LE DT 53 Virulizin ® 53 antitumor activity 53 ponatinib 53 Avastin bevacizumab 53 FOLOTYN ® 53 neratinib 53 cutaneous T cell 53 imetelstat 53 L MTP PE 53 Bezielle 53 dose escalation trial 53 relapsed multiple myeloma 53 Intravenous CP 53 IL# PE#QQR 53 Jevtana 53 anti EGFR antibody 53 radiation sensitizer 53 HGS ETR2 53 AeroLEF TM 53 Phase 2a trial 53 ularitide 53 novel VDA molecule 53 VEGF Trap 53 PEP# [003] 53 Phase IIb trials 53 Teysuno 53 mitogen activated ERK kinase 53 Tovaxin 53 SUCCEED trial 53 Reolysin 52 thymalfasin 52 Phase 1b clinical 52 entinostat 52 depsipeptide 52 rALLy clinical trial 52 relapsed refractory multiple myeloma 52 docetaxel Taxotere R 52 Alemtuzumab 52 darinaparsin 52 ATL# [001] 52 Ixempra 52 Evoltra R 52 fipamezole 52 Xcytrin 52 PEG PAL 52 GVAX immunotherapy 52 Exherin TM 52 IV NSCLC 52 oncological indications 52 Phase IIb clinical trials 52 lintuzumab 52 TheraSphere 52 heavily pretreated 52 IV Busulfex 52 Panzem R NCD 52 refractory Hodgkin lymphoma 52 THALOMID 52 OHR/AVR# 52 Carfilzomib 52 MoxDuo IR 52 metastatic hormone refractory 52 Annamycin 52 Rescula 52 Troxatyl 52 BENLYSTA 52 HDAC inhibitor 52 Onco TCS 52 celgosivir 52 pediatric glioma 52 enzastaurin 52 DXL# 52 BRAF inhibitor 52 Phase IIa trials 52 Phase IIb trial 52 CBLB# 52 Aplidin 52 Soliris eculizumab 52 deforolimus 52 pirfenidone 52 abiraterone acetate 52 Panzem R 52 pradefovir 52 PREOS R 52 docetaxel chemotherapy 52 PROSTVAC TM 52 BEMA Fentanyl 52 ACTEMRA 52 Increlex R 52 viral kinetic 52 R#/MEM # 52 DR Cysteamine 52 sumatriptan DosePro 52 TACI Ig 52 CR# vcMMAE 52 POSIDUR 52 Raptiva R 52 REVLIMID 52 PLK1 SNALP 52 cetuximab 52 Fibrillex TM 52 bevacizumab Avastin 52 IPLEX TM 52 Aptivus ® 52 Sebivo 52 Oncaspar 52 Nexavar 52 fluoropyrimidine 52 oral gallium 52 Indaflex TM 52 Azilect ® 52 PROCHYMAL 52 LidoPAIN SP 52 Aurexis 52 Æterna Zentaris 52 Halaven 52 Naglazyme 52 metastatic castration resistant 52 Hycamtin 52 Gliadel Wafer 52 silodosin 52 MGd 52 adecatumumab 52 Trastuzumab 52 Xeloda 52 Plicera 52 dacetuzumab 52 DP b# 52 preclinical 52 confirmatory Phase III 52 Orazol 52 oritavancin 52 XGEVA 52 INT# [002] 52 MabCampath 52 PRECISE trial 52 Rhucin 52 Actemra 52 PrevOnco ™ 52 INTERCEPT platelets 52 G#DT 52 FUSILEV ® 52 Evoltra 52 ocrelizumab 52 TPI ASM8 52 Hyphanox 52 Gefitinib 52 GRN#L 52 Myocet 52 B CLL 52 BCX# 52 erlotinib Tarceva ® 52 Mylotarg 52 MGCD# [002] 52 HuLuc# 52 Tanespimycin 52 Atiprimod 52 decitabine 52 PANVAC VF 52 taliglucerase alfa 52 investigational drug 52 Gemzar ® 52 INTELENCE 52 ZADAXIN ® 52 Phase IIb III 52 Lucanix R 52 velaglucerase alfa 52 Veronate 52 diabetic neuropathic pain 52 indibulin 52 lorvotuzumab mertansine 52 relapsed ovarian cancer 52 Civacir 52 RITUXAN 52 leading oral taxane 52 Onconase 52 Oxaliplatin 52 Zingo TM 52 ATL/TV# 52 Campath ® 52 capecitabine Xeloda R 52 metastatic melanoma 52 solid tumors 52 DAVANAT R 52 Viramidine 52 gemcitabine 52 Shigamabs R 52 Tarceva erlotinib 52 cancer immunotherapies 52 ROTATEQ 52 dirucotide MBP# 52 drug ISA# 52 teriflunomide 52 XIENCE V Stent System 52 rALLy trial 51 SYMMETRY trial 51 ORENCIA R 51 AVONEX ® 51 BIBW 51 eculizumab 51 Revlimid lenalidomide 51 Vandetanib 51 BRIM2 51 bevacizumab Avastin ® 51 pitavastatin 51 Lupuzor 51 Zerenex 51 Diamyd ® 51 tremelimumab 51 REPLAGAL 51 HuMax CD# 51 CD# antibody [001] 51 volociximab 51 advanced NSCLC 51 Solasia 51 lymphoma CTCL 51 DC Bead 51 CORLUX 51 Alzhemed TM 51 Phenoptin 51 FavId 51 Stimuvax R 51 MEK inhibitor 51 Xanafide 51 eprotirome 51 Excellagen 51 darinaparsin ZIO 51 rNAPc2 51 RAPAFLO 51 CIMYM 51 BNC# 51 sNDA submission 51 metastatic castrate resistant 51 CLARITY study 51 palliative radiotherapy 51 MEK inhibitor RDEA# 51 Anturol 51 orphan designation 51 Factor VIIa 51 TKM ApoB 51 perifosine KRX 51 MAXY alpha 51 IND submission 51 Nexavar sorafenib 51 Tarceva 51 investigational therapies 51 Sosei 51 HRPC 51 cariprazine 51 DCVax ® 51 Mozobil 51 glatiramer acetate 51 MDV# 51 plus gemcitabine 51 cytarabine 51 nitazoxanide 51 Fludara ® 51 multicenter Phase 51 daclizumab 51 phase IIa 51 R sorafenib tablets 51 platinum refractory 51 multiple myeloma MM 51 Phase #/#a trial 51 PEG Interferon lambda 51 #I TM# 51 ZACTIMA 51 pafuramidine 51 trastuzumab 51 Phase III randomized controlled 51 MEPACT 51 NEUPOGEN 51 Asentar 51 NUVIGIL 51 ELND# 51 Curaxin 51 Nanobody 51 Diabetic Macular Edema 51 GTC recombinant human 51 anticancer compound 51 VPRIV 51 MAA submission 51 recurrent GBM 51 ABRAXANE TM 51 Tarvacin 51 ALN TTR 51 Combination REOLYSIN R 51 sunitinib malate 51 liver metastases 51 Mepact 51 paclitaxel 51 Cleviprex TM clevidipine 51 L BLP# 51 mitoxantrone 51 AzaSite Xtra 51 DPX Survivac 51 trastuzumab Herceptin R 51 natalizumab 51 Evoltra ® 51 Protexia R 51 Serdaxin 51 ATryn ® 51 taxane 51 dasatinib 51 refractory APL 51 Cetrorelix 51 oral fludarabine 51 Onalta 51 forodesine HCl 51 Velcade bortezomib 51 dose cohort 51 ALD# 51 bortezomib 51 Augment Injectable 51 metastatic bladder 51 tolevamer 51 ProSavin 51 viral kinetics 51 topical NSAID 51 lenalidomide Revlimid R 51 ZEFTERA TM Zevtera TM 51 pomalidomide 51 lurasidone 51 StemEx 51 CA4P 51 Zevalin 51 Ceftobiprole 51 metastatic HRPC 51 Hsp# inhibitor 51 Phase IIa clinical 51 nab paclitaxel 51 non squamous NSCLC 51 ospemifene 51 vascular disrupting agent 51 TRANSDUR Sufentanil 51 Azedra TM 51 Personalized Immunotherapy 51 Zavesca r 51 ZK EPO 51 heavily pretreated patients 51 TroVax ® 51 golimumab 51 Orphan Drug designations 51 PRTX 51 rituximab 51 SAR# [004] 51 RNAi therapeutic 51 ENMD 51 CANCIDAS 51 BST CarGel R 51 LEUKINE 51 cell lymphoma CTCL 51 brivaracetam 51 placebo controlled clinical 51 vascular disrupting agents 51 recurrent malignant glioma 51 COPAXONE ® 51 sorafenib tablets 51 CCX# 50 confirmatory Phase 3 50 FACTIVE 50 Bradmer 50 Voraxaze 50 Homspera 50 dabigatran etexilate 50 oral FTY# 50 Dapagliflozin 50 toremifene 50 combination REOLYSIN R 50 anticancer therapies 50 ASONEP 50 INCB# [003] 50 EGRIFTA TM 50 KNS # 50 Phase 2b 50 Kepivance 50 Aflibercept 50 M Vax 50 oral mucositis 50 hepatocellular carcinoma 50 GVAX 50 PROVENGE sipuleucel T 50 Treanda 50 Campath 50 antibody MAb 50 IMiDs 50 dacarbazine 50 PS# [001] 50 Prestara 50 ceftaroline 50 NXL# 50 arimoclomol 50 rFVIIIFc 50 monotherapy 50 faropenem 50 resminostat 50 ORENCIA ® 50 OZURDEX ® 50 AeroLEF 50 hepatocellular cancer 50 randomized Phase III 50 alvimopan 50 Orphan Drug Designation 50 bile duct tumor 50 MAXY G# 50 multicenter clinical 50 RDEA# 50 metastatic CRC 50 Octreolin 50 GRASPA ® 50 AGGRASTAT ® 50 cetuximab Erbitux ® 50 Clevudine 50 GED aPC 50 neoadjuvant 50 JAK1 50 PRX# 50 recurrent glioblastoma 50 IAP inhibitors 50 DOS# 50 docetaxel Taxotere 50 Panzem 50 RAV# 50 TASQ 50 G CSF 50 Dyloject 50 oral antiviral 50 RELISTOR 50 placebo controlled Phase III 50 mRCC 50 ATL# [002] 50 TG# [001] 50 OvaRex MAb 50 indolent NHL 50 randomized controlled Phase 50 PHX# 50 phase IIb III 50 atacicept 50 ZENPEP 50 telbivudine 50 epothilone 50 Onalta ™ 50 SCCHN 50 BYDUREON 50 DU #b 50 immunotherapeutic 50 cytotoxic chemotherapy 50 BRAF V# mutation 50 edoxaban 50 lomitapide 50 azacitidine 50 maribavir 50 vismodegib 50 recurrent metastatic 50 oral salmon calcitonin 50 Arzerra ofatumumab 50 laninamivir 50 Rebif ® 50 PDE4 inhibitor 50 clinical pharmacology studies 50 Delcath PHP System 50 pegylated liposomal doxorubicin 50 active moiety 50 RRMS patients 50 SIMPONI 50 bazedoxifene 50 topotecan 50 Zenvia ™ 50 Octreotide 50 tyrosine kinase inhibitor 50 Phase Ib clinical trials 50 panitumumab Vectibix 50 ADAGIO study 50 hypoxia activated prodrug 50 clinical 50 Japanese Encephalitis vaccine 50 recurrent refractory 50 Mycamine 50 LUX Lung 50 Luteinizing Hormone Releasing Hormone 50 CTCL 50 prostate cancer CRPC 50 tolerability 50 CD# monoclonal antibody 50 peginesatide 50 noninfectious uveitis 50 SinuNase 50 oral calcitonin 50 CRLX# 50 Allovectin 7 r 50 Clolar ® 50 bevacizumab 50 NVA# 50 AVE# 50 lubiprostone 50 personalized immunotherapy 50 relapsed SCLC 50 Pirfenidone 50 investigational monoclonal antibody 50 AzaSite 50 Phase #b/#a clinical 50 Xcytrin R 50 ReN# 50 QRxPharma 50 BEMA TM Fentanyl 50 paliperidone ER 50 CYC# 50 Trizytek 50 radiolabeled TM# 50 Erbitux 50 Belinostat 50 CLORETAZINE TM VNP#M 50 Ophena 50 INC# 50 CIMZIA ™ 50 IV metastatic melanoma 50 Trofex 50 angioedema indications 50 preclinical efficacy 50 Restanza 50 GRN# 50 Solazed ™ 50 cytotoxic 50 Phase III 50 chemotherapeutic drug 50 Onrigin 50 refractory acute myeloid 50 SEBIVO 50 TAXUS Element Stent System 50 carboplatin 50 soft tissue sarcomas 50 durable remissions 50 ALGRX 50 XIAFLEX 50 rBChE 50 Xeloda capecitabine 50 Cimzia TM 50 huN# DM1 50 Daclizumab 50 ADVANCE PD 50 Bortezomib 50 crofelemer 50 anti angiogenic therapy 50 low dose cytarabine 50 Erbitux cetuximab 50 Aviptadil 50 PSN# [002] 50 Marketing Authorisation Application 50 pharmacokinetic PK study 50 AA amyloidosis 50 PEGylated interferon beta 1a 50 PhosLo 50 ARRY # 50 Taxotere docetaxel 50 oral methylnaltrexone 50 telomerase therapeutic 50 Iluvien 50 Ampligen r 50 metastatic GIST 50 Cimzia ® 50 Romidepsin 50 investigational compound 50 ADVEXIN p# therapy 50 XYOTAX TM 49 Mycograb 49 YONDELIS R 49 trastuzumab emtansine T DM1 49 Specifid 49 paclitaxel cisplatin 49 MNTX 49 immunogenicity 49 pediatric acute lymphoblastic 49 Xerecept 49 leukemia APL 49 Neupogen ® 49 triphendiol 49 TroVax 49 therapeutic antibody 49 LC#m# 49 Manja Bouman CEO 49 CYCLOSET 49 NEUVENGE 49 PI3K/Akt pathway inhibitor 49 neuroendocrine tumors 49 ostarine 49 VitiGam 49 telavancin 49 CIMZIA TM 49 PD LID 49 Fabry Disease 49 mCRC patients 49 Chrysalin 49 SPIRIT III 49 placebo controlled Phase 49 DOXIL 49 RSD# oral 49 Gleevec Glivec 49 pegloticase 49 omacetaxine mepesuccinate 49 tubulin inhibitor 49 iSONEP 49 LBH# 49 MAbs 49 PLX# 49 TG# [003] 49 Bendamustine 49 relapsed MCL 49 Xelox 49 Alvesco R 49 Rhucin R 49 paclitaxel Taxol ® 49 MOR# 49 anti CD# antibodies 49 Phase #/#a 49 Trovax 49 BRIM3 49 Li Fraumeni Syndrome 49 GSK# [001] 49 stage IIIB 49 NEVO ™ 49 Phase III HEAT 49 Rhucin ® 49 Behcet uveitis 49 BiovaxID TM